Our understanding of the molecular biology of cancer has improved dramatically over the past thirty years, and many potential therapeutic agents have been developed. However a way to realize the full clinical potential of these agents has yet to be found. Our hypothesis is that a therapeutic agent must satisfy two requirements to be effective: (1) the agent must be delivered to the target cells in vivo in optimal quantities, remaining there for an appropriate time at sufficient concentrations, and (2) the agent must be effective in the in vivo microenvironment of primary and metastatic tumors. We also hypothesize that creative manipulation of the tumor microenvironment will significantly improve the delivery and effectiveness of many types of therapeutic agents. This Program Project Grant (PPG) application builds on these premises. Our primary objective is to develop a quantitative understanding of the physiological barriers to the delivery and effectiveness of conventional and novel therapeutic agents used for solid tumor treatment. Our secondary objective is to seek strategies with the potential to overcome these barriers. One of the strengths of our PPG is development and utilization of state-of-the-art optical imaging techniques. However, due to rapid progress and unusually high productivity of all projects of this PPG (as documented by publications in journals such as Science, Nature, Nature Medicine, Nature Reviews Cancer, PNA5 and Circulation Research in the past 12 months), demand for our high resolution in vivo, ex vivo, and in vitro imaging has significantly increased. Therefore, the availability of these imaging resources has become a limiting factor in our effort to continue to make progress. In this Supplement request, we propose to obtain 1) a Multi-photon Laser Scanning Microscope Work Station to be housed within our gnotobiotic animal facility for in vivo imaging of regions deep inside tumors, and 2) a Confocal Laser Scanning Microscope Work Station which will be located outside the animal facility for high resolution ex vivo and in vitro imaging. The new systems will fill the urgent need to image specific molecular, cellular, anatomical and functional parameters in normal and tumor tissues in mice during tumor growth, regression, relapse and metastasis, and will make these novel imaging resources available to all projects in our PPG. This equipment will also fill the critical needs of our NCI supported Bioengineering Research Partnership Grant, R24 CA-85146. The proposed imaging equipment, in combination with our expertise in biomedical engineering and cancer research, will provide the power to uncover molecular mechanisms of blood and lymph angiogenesis, as well as the invasion and metastasis of tumors. Interdisciplinary research, our major strength, will be further enhanced by complementary functional imaging and common image analysis approaches enabled with this Supplement. ? ? ? COLLABORATING INSTITUTION (S): None ? ? ? PROGRESS IN THE CURRENT FUNDING PERIOD: During the current funding period, Dr. Jain and his colleagues have published 44 original articles and 15 reviews that are attributed to the program project grant CA080124. There are 15 publications and 6 abstracts attributed to the R24 CA085146 grant. This clearly demonstrates that the investigators are active, productive scientists whose work is accepted by top-level journals, and that research progress is progressing well. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA080124-03S1
Application #
6673208
Study Section
Subcommittee G - Education (NCI)
Program Officer
Stone, Helen B
Project Start
2000-08-11
Project End
2003-07-31
Budget Start
2002-08-01
Budget End
2003-07-31
Support Year
3
Fiscal Year
2003
Total Cost
$418,679
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Ina Ly, K; Vakulenko-Lagun, Bella; Emblem, Kyrre E et al. (2018) Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep 8:17062
Nowak-Sliwinska, Patrycja; Alitalo, Kari; Allen, Elizabeth et al. (2018) Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis 21:425-532
Zhao, Yingchao; Liu, Pinan; Zhang, Na et al. (2018) Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A 115:E2077-E2084
Hong, Theodore S; Grassberger, Clemens; Yeap, Beow Y et al. (2018) Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy. NPJ Precis Oncol 2:22
Pinter, Matthias; Kwanten, Wilhelmus J; Jain, Rakesh K (2018) Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events. Clin Cancer Res 24:3803-3812
Arvanitis, Costas D; Askoxylakis, Vasileios; Guo, Yutong et al. (2018) Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption. Proc Natl Acad Sci U S A 115:E8717-E8726
Khandekar, Melin J; Jain, Rakesh (2018) Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. Transl Cancer Res 7:S16-S20
Stylianopoulos, Triantafyllos; Munn, Lance L; Jain, Rakesh K (2018) Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy. Trends Cancer 4:258-259
Grassberger, Clemens; Hong, Theodore S; Hato, Tai et al. (2018) Differential Association Between Circulating Lymphocyte Populations With Outcome After Radiation Therapy in Subtypes of Liver Cancer. Int J Radiat Oncol Biol Phys 101:1222-1225
Zhang, Na; Chen, Jie; Ferraro, Gino B et al. (2018) Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol 299:326-333

Showing the most recent 10 out of 320 publications